The Ludwig Boltzmann Institute Applied Diagnostics in Vienna, Austria, follows a new dual biomarker concept for tumour diagnosis and treatment. The focus of the institute lies on the development of non-invasive diagnostic methods combining molecular epigenetic and genetic
signatures and molecular imaging biomarkers for PET/SPECT analysis and radioendotherapy.
For a project funded by Industrial Collaborations Partners we have an open position with immediate start date for a postdoctoral fellow (1 year with a potential extension for a 2 nd year after successful evaluation) in the area of radiotracer development within the institute’s program line Imaging Biomarkers. The project involves the development of novel chelators for
non-standard metallic radionuclides. Candidates with a adiopharmaceutical background and the desire to get involved in application-driven and translational research are encouraged to apply. The candidates will work in a stimulating, interdisciplinary environment (radiopharmacy, nuclear medicine, chemistry, pharmacology and health economics) at the Medical University of Vienna and the University of Vienna.
Desired Skills and Experience:
– Ph.D. degree in Radiopharmaceuticals Science or equivalent.
– Know-how in conducting radiometal-labelling reactions and analysis of the radiolabelled products (e.g., TLC&HPLC, stability assays).
– Experience in conducting biological assays (in vitro/in vivo) would be advantageous.
– Good communication skills in English and/or German.
– Motivation to work in a transdisciplinary research team
Kontakt: Prof. Dr. Thomas Mindt: Thomas.Mindt[ät]lbiad.lbg.ac.at